Lilly’s TOGETHER-PsA study presents compelling Phase 3b data demonstrating that the combination of Taltz (ixekizumab) and Zepbound (tirzepatide) significantly enhances treatment outcomes for adults with psoriatic arthritis (PsA) and obesity. This late-breaking research, unveiled at the AAD Annual Meeting and published in Arthritis & Rheumatology, reveals that the dual therapy achieved superior efficacy across primary and secondary endpoints compared to Taltz monotherapy, with notable improvements in disease activity as early as Week 4.

The findings underscore the potential of this combination therapy to address not only PsA but also the associated metabolic challenges faced by approximately 65% of adults with the condition who are also obese. Participants receiving both treatments exhibited a substantial reduction in PsA disease activity (ACR50) and a marked increase in achieving Minimal Disease Activity (MDA). Furthermore, improvements were observed in fatigue, physical function, mental health-related quality of life, and various cardiometabolic parameters, including BMI and blood pressure. These results highlight the dual role of Taltz in modulating inflammation via IL-17A inhibition and Zepbound’s impact on weight management through its action as a dual GIP and GLP-1 receptor agonist.

The implications of these findings are significant for the field of aging and chronic disease management. The successful integration of therapies targeting both inflammatory and metabolic pathways may shift current research paradigms, emphasizing the need for comprehensive treatment strategies that concurrently address multiple comorbidities. This approach could expedite drug development timelines by paving the way for combination therapies that enhance patient outcomes, ultimately improving healthspan and quality of life for those affected by PsA and obesity.

Source: investor.lilly.com